PUBLISHER: The Business Research Company | PRODUCT CODE: 1694907
PUBLISHER: The Business Research Company | PRODUCT CODE: 1694907
Respiratory diseases encompass a broad spectrum of conditions that impact the airways and lungs, resulting in respiratory symptoms and compromised breathing. Respiratory disease vaccines, on the other hand, pertain to a category of immunizations specifically formulated to shield individuals from respiratory infections caused by viruses or bacteria that primarily target the respiratory system, which includes the lungs and air passages. These vaccines function by activating the immune system to generate antibodies capable of identifying and combatting the particular pathogens responsible for these diseases.
The primary classifications of respiratory disease vaccines encompass viral vaccines, bacterial vaccines, and combination vaccines. Viral vaccines consist of formulations containing weakened or inactivated viruses. They serve to stimulate immune responses and are instrumental in the prevention of respiratory diseases by instructing the immune system to recognize and mount defenses against distinct viruses. This, in turn, reduces the spread and severity of infections. These vaccines find application in combatting illnesses such as COVID-19, influenza, respiratory syncytial virus (RSV), pneumonia, among others, and are administered to individuals spanning various age groups, including infants, adolescents, and adults, within clinical, hospital, and other healthcare settings.
The respiratory diseases vaccine market research report is one of a series of new reports from The Business Research Company that provides respiratory diseases vaccine market statistics, including respiratory diseases vaccine industry global market size, regional shares, competitors with a respiratory diseases vaccine market share, detailed respiratory diseases vaccine market segments, market trends and opportunities and any further data you may need to thrive in the respiratory diseases vaccine industry. This respiratory diseases vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The respiratory disease vaccine market size has grown marginally in recent years. It will grow from $69.99 billion in 2024 to $70.9 billion in 2025 at a compound annual growth rate (CAGR) of 1.3%. The growth in the historic period can be attributed to rising prevalence of respiratory diseases, increased public vaccination awareness, public health initiatives, growing demand for effective and more tolerable vaccines.
The respiratory disease vaccine market size is expected to see steady growth in the next few years. It will grow to $79.16 billion in 2029 at a compound annual growth rate (CAGR) of 2.8%. The growth in the forecast period can be attributed to aging population, rising healthcare spending, investments in vaccine, pandemic preparedness. Major trends in the forecast period include innovative vaccines, collaborative research, advancement in vaccine development, drug approval.
The increasing incidence of tuberculosis (TB) is expected to drive the growth of the respiratory disease vaccine market. TB is a serious infectious disease primarily affecting the lungs, caused by the bacterium Mycobacterium tuberculosis. It can lead to severe complications if not treated adequately, making the development and distribution of vaccines crucial in controlling its spread. The rising number of TB cases has highlighted the need for enhanced vaccination efforts to reduce transmission and improve public health outcomes. For example, in November 2023, the Centers for Disease Control and Prevention (CDC) reported that the United States saw 8,331 TB cases in 2022, marking a 5.9% increase compared to 2021. The incidence rate also rose by 5.5%, reaching 2.5 cases per 100,000 people. This upward trend in TB cases underlines the growing demand for vaccines and other preventive measures, which in turn will fuel the expansion of the respiratory disease vaccine market.
The increasing prevalence of smoking is poised to be a driving factor in the prospective growth of the respiratory disease vaccine market. Smoking entails the inhalation and exhalation of smoke emanating from the combustion of tobacco or tobacco-containing products, posing a multitude of health hazards, including tracheitis, heart disease, stroke, and various forms of cancer. Respiratory disease vaccines play a crucial role in providing a measure of protection against specific infections for individuals who engage in smoking. For instance, data from Statistics Canada in July 2022 highlighted a 5.8% upsurge in cigarette production compared to June 2021. Additionally, the total volume of cigarettes sold increased by 1.3% from May 2022, reaching a total of 1.4 billion in June 2022. Consequently, the growing incidence of smoking is a driving force behind the expansion of the respiratory disease vaccine market.
Leading companies in the respiratory disease vaccine market are committed to the development of innovative products aimed at bolstering their effectiveness, providing advanced solutions for the prevention and treatment of respiratory infections. For instance, in May 2023, Pfizer Inc., a U.S.-based pharmaceutical company, secured approval from the Food and Drug Administration (FDA) for ABRYSVO (Respiratory Syncytial Virus Vaccine). This bivalent vaccine, featuring the respiratory syncytial virus prefusion F (RSVpreF) vaccine, is designed for the prevention of lower respiratory tract disease stemming from respiratory syncytial virus in individuals aged 60 years and above. ABRYSVO comprises unadjuvanted vaccine components, with two preF proteins meticulously tailored to optimize immunity against both RSV A and B strains. Clinical trials have demonstrated the vaccine's safety and efficacy.
In August 2022, GSK PLC, a biopharmaceutical company headquartered in the UK, completed the acquisition of Affinivax Inc. The financial details of the acquisition were not disclosed. This strategic move reaffirms GSK Plc's dedication to innovation in the realm of pharmaceuticals and vaccines, including its commitment to the development of a next-generation 24-valent pneumococcal vaccine candidate known as AFX3772. Affinivax Inc., a clinical-stage biotechnology company based in the United States, specializes in the development of vaccines and immunotherapies targeted at a range of diseases, with a particular focus on respiratory ailments.
Major companies operating in the respiratory disease vaccine market are Pfizer Inc., Johnson & Johnson Ltd., Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, GlaxoSmithKline PLC, Sinovac Biotech Co. Ltd., Moderna Inc., BioNTech SE, CSL Limited, Daiichi Sankyo Company Limited, Mitsubishi Tanabe Pharma Corporation, Novavax Inc., Emergent BioSolutions Inc., Seqirus, Bio Farma, Dynavax Technologies Corporation, Hualan Biological Bacterin Co. Ltd., Serum Institute of India Pvt. Ltd., Bavarian Nordic A/S, Valneva SE, Biological E. Limited, CanSino Biologics Inc., Bharat Biotech International Limited, Medicago Inc., CureVac N.V., Incepta Vaccine Ltd., Inovio Pharmaceuticals Inc., Ology Bioservices, VBI Vaccines Inc.
Asia-Pacific was the largest region in the respiratory disease vaccine market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in respiratory diseases vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the respiratory diseases vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The respiratory diseases vaccine market consists of sales of the rotavirus vaccine, bordetella vaccine and varicella (chickenpox) vaccine. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Respiratory Disease Vaccine Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on respiratory disease vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for respiratory disease vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The respiratory disease vaccine market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.